Stockscreener 앱 받기
137.75
6.70%
8.65
전일 마감가:
$129.10
열려 있는:
$130.04
하루 거래량:
1.48M
Relative Volume:
1.74
시가총액:
$6.54B
수익:
$338.46M
순이익/손실:
$-310.96M
주가수익비율:
-21.09
EPS:
-6.53
순현금흐름:
$-132.82M
1주 성능:
+5.03%
1개월 성능:
+43.22%
6개월 성능:
+56.69%
1년 성능:
+67.76%
1일 변동 폭
$128.38
$139.13
1주일 범위
$124.03
$139.13
52주 변동 폭
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
137.75 | 6.54B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-12-31 | 재확인 | Mizuho | Outperform |
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Q1 Earnings Estimate for AXSM Issued By HC Wainwright - MarketBeat
William Blair Issues Negative Outlook for AXSM Earnings - MarketBeat
FY2025 EPS Estimate for Axsome Therapeutics Cut by Analyst - MarketBeat
Leerink Partnrs Brokers Increase Earnings Estimates for AXSM - MarketBeat
Axsome Therapeutics stock soars to all-time high of $134.2 By Investing.com - Investing.com Nigeria
Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Axsome Therapeutics stock soars to all-time high of $134.2 - Investing.com India
Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Astrazeneca, Vertex, Axsome secure US FDA approvals in January - BioWorld Online
Axsome Therapeutics targets multiple NDA submissions and pipeline advancements through 2025 - MSN
Mizuho maintains Axsome Outperform rating, $195 target - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $200.00 at HC Wainwright - MarketBeat
FY2028 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat
Axsome Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Peregrine Capital Management LLC - MarketBeat
Strategic Financial Concepts LLC Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - AOL
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN
Axsome Therapeutics (NASDAQ:AXSM) Receives Outperform Rating from William Blair - MarketBeat
Truist Financial Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering (NASDAQ:AXSM) - Seeking Alpha
Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics Revenue Surges 66% - MSN
Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 - MSN
Axsome Therapeutics (NASDAQ:AXSM) Shares Gap DownTime to Sell? - MarketBeat
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
William Blair Reiterates Outperform Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
RBC Capital Adjusts Price Target on Axsome Therapeutics to $192 From $143, Keeps Outperform Rating - Marketscreener.com
Axsome Therapeutics price target raised to $153 from $133 at Needham - TipRanks
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2024 Earnings Call Transcript - Insider Monkey
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $200 From $176, Maintains Buy Rating - Marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Stock Quotes, Forecast and News Summary - Benzinga
Axsome: Q4 Earnings Snapshot - CT Insider
Axsome Therapeutics (AXSM) to Release Quarterly Earnings on Tuesday - MarketBeat
Axsome Therapeutics, Penumbra, Republic Services - TradingView
Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Axsome Therapeutics Sees Robust Growth and Strategic Progress - TipRanks
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? - MSN
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth - MSN
Truist Securities Raises Price Target on Axsome Therapeutics to $200 From $190, Keeps Buy Rating - Marketscreener.com
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst - Benzinga
Earnings call transcript: Axsome misses Q4 2024 forecasts, stock dips By Investing.com - Investing.com South Africa
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates - MSN
Axsome Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Axsome misses Q4 2024 forecasts, stock dips - Investing.com
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript - MSN
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Option Exercise |
3.50 |
3,000 |
10,500 |
45,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 13 '25 |
Sale |
129.86 |
12,000 |
1,558,320 |
42,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Sale |
131.07 |
3,000 |
393,210 |
42,187 |
0.27%
3.05%
자본화:
|
볼륨(24시간):